

# WEST Search History

DATE: Monday, November 20, 2006

<u>Hide?</u>	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
<i>DB=PGPB,USPT,JPAB,DWPI; PLUR=YES; OP=ADJ</i>			
<input type="checkbox"/>	L4	L1 and rapa\$	24
<input checked="" type="checkbox"/>	L3	L1 same rapa\$	0
<input checked="" type="checkbox"/>	L2	L1 and CRD	4
<input checked="" type="checkbox"/>	L1	instab\$ near3 mRNA	409

END OF SEARCH HISTORY

\$%^STN;HighlightOn= \*\*\*;HighlightOff=\*\*\* ;

Connecting via WInsock to STN

Welcome to STN International! Enter xx

LOGINID:ssspla1633cxq

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive  
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced  
NEWS 5 AUG 30 CA(SM)/Cplus(SM) Austrian patent law changes  
NEWS 6 SEP 11 CACplus enhanced with more pre-1907 records  
NEWS 7 SEP 21 CA/Cplus fields enhanced with simultaneous left and right truncation  
NEWS 8 SEP 25 CA(SM)/Cplus(SM) display of CA Lexicon enhanced  
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates  
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for prolylserine  
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme  
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes  
NEWS 13 OCT 19 E-mail format enhanced  
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available  
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in multiple databases  
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded  
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 18 NOV 03 JAPICO enhanced with IPC 8 features and functionality  
NEWS 19 NOV 10 CA/Cplus F-Term thesaurus enhanced  
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available  
NEWS 21 NOV 13 CA/Cplus pre-1967 chemical substance index entries enhanced with preparation role

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c,  
CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 14:18:10 ON 20 NOV 2006

=>  
=> FIL EMBASE BIOSIS CAPLUS  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 5.25 5.25

FILE 'EMBASE' ENTERED AT 14:33:18 ON 20 NOV 2006  
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 14:33:18 ON 20 NOV 2006  
Copyright (c) 2006 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 14:33:18 ON 20 NOV 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s coding region instability determinant  
L1 21 CODING REGION INSTABILITY DETERMINANT

=> dup rem l1

PROCESSING COMPLETED FOR L1  
L2 9 DUP REM L1 (12 DUPLICATES REMOVED)

=> d bib abs 1-  
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y(N):y

L2 ANSWER 1 OF 9 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 1  
AN 2006108605 EMBASE <<LOGINID::20061120>>  
TI Analysis of RNA-protein interactions by a microplate-based fluorescence anisotropy assay.  
AU Mao C.; Flavin K.G.; Wang S.; Dodson R.; Ross J.; Shapiro D.J.  
CS D.J. Shapiro, Department of Biochemistry, University of Illinois, 600 South Mathews Avenue, Urbana, IL 61801-3602, United States.  
djshapin@uiuc.edu  
SO Analytical Biochemistry, (15 Mar 2006) Vol. 350, No. 2, pp. 222-232..  
Refs: 53  
ISSN: 0003-2697 E-ISSN: 1096-0309 CODEN: ANBCA2  
PUI S 0003-2697(05)00885-7  
CY United States  
DT Journal Article  
FS 029 Clinical Biochemistry  
LA English  
SL English  
ED Entered STN: 20 Mar 2006  
Last Updated on STN: 20 Mar 2006  
AB Quantitative studies of RNA-protein interactions are quite cumbersome using traditional methods. We developed a rapid microplate-based fluorescence anisotropy (FA)fluorescence polarization assay that works well, even with RNA probes >90 nucleotides long. We analyzed binding of RNA targets by vigilin/DDP1/SCP160p and by c-myc \*\*\*coding\*\*\* \*\*\*region\*\*\* \*\*\*instability\*\*\* \*\*\*determinant\*\*\* (CRD) binding protein, CRD-BP. Vigilin is essential for cell viability and functions in heterochromatin formation and mRNA decay. The CRD-BP stabilizes c-myc mRNA. Vigilin bound to a vitellogenin mRNA 3'-UTR probe with a two to three-fold lower affinity than to a Drosophila dodecasatellite ssDNA binding site and bound to the c-myc CRD with a two- to three-fold lower affinity than to the vitellogenin mRNA 3'-UTR. Competition between vigilin and CRD-BP for binding to the CRD may therefore play a role in regulating c-myc mRNA degradation. We analyzed suitability of the microplate-based FA assay for high-throughput screening for small-molecule regulators of RNA-protein interactions. The assay exhibits high reproducibility and precision and works well in 384-well plates and in 5 .mu.l to 20 .mu.l samples. To demonstrate the potential of this assay for screening libraries of small molecules to identify novel regulators of RNA-protein interactions, we identified neomycin and H33342 as inhibitors of binding of vigilin to the vitellogenin mRNA 3'-UTR. .COPYRGT. 2005 Elsevier Inc. All rights reserved.

L2 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:371698 CAPLUS <<LOGINID::20061120>>  
DN 143:170376  
TI Detection of CRD-BP mRNA in peripheral blood of colorectal cancer patients by fluorescent real-time nested RT-PCR  
AU Wang, Fangjin; He, Yunshao; Zhang, Changhua; He, Yulong; Cheng, Gang  
CS Department of Anatomy, Medical College, Sun Yat-sen University, Guangzhou, 510080, Peop. Rep. China  
SO Linchuang Jianyan Zazhi (Nanjing, China) (2005), 23(2), 120-122  
CODEN: LJZNA; ISSN: 1001-764X  
PB Linchuang Jianyan Zazhi Bianji  
DT Journal  
LA Chinese  
AB Objective: To investigate the expression level of CRD-BP ( \*\*\*coding\*\*\* \*\*\*region\*\*\* \*\*\*instability\*\*\* \*\*\*determinant\*\*\* -binding protein) mRNA in peripheral blood of colorectal cancer patients and est. the availability of CRD-BP as a marker of colorectal cancer. Methods: Peripheral blood samples were collected from 64 colorectal cancer patients, 20 non-cancerous patients and 25 healthy adults. The expression level of CRD-BP mRNA in peripheral blood was detected by fluorescent real-time nested reverse transcriptase-polymerase chain reaction (RT-PCR). PCR product was cloned into PUC19 vector and sequenced. Results: In the research group 28 samples (43.8%) showed pos. expression of CRD-BP mRNA, while none was pos. in controls with an obvious difference ( $\chi^2 = 26.493$ ,  $P < 0.001$ ). There was a significant correlation between CRD-BP mRNA expression and Dukes stage of colorectal cancer ( $\chi^2 = 8.195$ ,  $P < 0.05$ ). Conclusion: CRD-BP mRNA may be detectable in peripheral blood of colorectal cancer patients and should be a useful tumor marker in peripheral blood for clin. diagnosis of colorectal cancer.

L2 ANSWER 3 OF 9 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 2  
AN 2004041038 EMBASE <<LOGINID::20061120>>  
TI Mammary Tumor Induction in Transgenic Mice Expressing an RNA-Binding Protein.  
AU Tessier C.R.; Doyle G.A.; Clark B.A.; Pitot H.C.; Ross J.  
CS J. Ross, University of Wisconsin-Madison, McArdle Lab. for Cancer Research, 1400 University Avenue, Madison, WI 53706, United States.  
ross@oncology.wisc.edu  
SO Cancer Research, (1 Jan 2004) Vol. 64, No. 1, pp. 209-214..  
Refs: 40  
ISSN: 0008-5472 CODEN: CNREAB

CY United States  
DT Journal; Article  
FS 005 General Pathology and Pathological Anatomy  
016 Cancer  
022 Human Genetics  
LA English  
SL English  
ED Entered STN: 20 Feb 2004

Last Updated on STN: 20 Feb 2004

AB We have analyzed mammary tumors arising in transgenic mice expressing a novel, multifunctional RNA-binding protein. The protein, which we call the c-myc mRNA \*\*\*coding\*\*\* \*\*\*region\*\*\* \*\*\*instability\*\*\* \*\*\*determinant\*\*\* binding protein (CRD-BP), binds to c-myc, insulin-like growth factor II, and beta-actin mRNAs, and to H19 RNA. Depending on the RNA substrate, the CRD-BP affects RNA localization, translation, or stability. CRD-BP levels are high during fetal development but low or undetectable in normal adult tissues. The CRD-BP is linked to tumorigenesis, because its expression is reactivated in some adult human breast, colon, and lung tumors. These data suggest the CRD-BP is a proto-oncogene. To test this idea, the CRD-BP was expressed from the whey acidic protein (WAP) promoter in mammary epithelial cells of adult transgenic mice. The incidence of mammary tumors was 95% and 60% in two lines of WAP-CRD-BP mice with high and low relative CRD-BP expression, respectively. Some of the tumors metastasized. Nontransgenic mice did not develop mammary tumors. H19 RNA and insulin-like growth factor II mRNA were up-regulated significantly in non-neoplastic WAP-CRD-BP mammary tissue. WAP-CRD-BP mice are a novel model for mammary neoplasia and might provide insights into human breast cancer biology.

L2 ANSWER 4 OF 9 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 3  
AN 2002189910 EMBASE <>LOGINID::20061120>>  
TI Regulation of c-myc mRNA decay by translational pausing in a \*\*\*coding\*\*\* \*\*\*region\*\*\* \*\*\*instability\*\*\* \*\*\*determinant\*\*\*

AU Lemm I.; Ross J.  
CS J. Ross, McArdle Lab, for Cancer Research, University of Wisconsin-Madison, 1400 University Ave., Madison, WI 53706, United States.  
ross@oncology.wisc.edu

SO Molecular and Cellular Biology, (2002) Vol. 22, No. 12, pp. 3959-3969..  
Refs: 65  
ISSN: 0270-7306 CODEN: MCEBD4  
CY United States  
DT Journal; Article  
FS 029 Clinical Biochemistry  
LA English  
SL English  
ED Entered STN: 27 Jun 2002

Last Updated on STN: 27 Jun 2002

AB A 249-nucleotide \*\*\*coding\*\*\* \*\*\*region\*\*\* \*\*\*instability\*\*\* \*\*\*determinant\*\*\* (CRD) destabilizes c-myc mRNA. Previous experiments identified a CRD-binding protein (CRD-BP) that appears to protect the CRD from endonuclease cleavage. However, it was unclear why a CRD-BP is required to protect a well-translated mRNA whose coding region is covered with ribosomes. We hypothesized that translational pausing in the CRD generates a ribosome-deficient region downstream of the pause site, and this region is exposed to endonuclease attack unless it is shielded by the CRD-BP. Transfection and cell-free translation experiments reported here support this hypothesis. Ribosome pausing occurs within the c-myc CRD in tRNA-depleted reticulocyte translation reactions. The pause sites map to a rare arginine (CGA) codon and to an adjacent threonine (ACA) codon. Changing these codons to more common codons increases translational efficiency in vitro and increases mRNA abundance in transfected cells. These data suggest that c-myc mRNA is rapidly degraded unless it is (i) translated without pausing or (ii) protected by the CRD-BP when pausing occurs. Additional mapping experiments suggest that the CRD is bipartite, with several upstream translation pause sites and a downstream endonuclease cleavage site.

L2 ANSWER 5 OF 9 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 4  
AN 2003458265 EMBASE <>LOGINID::20061120>>

TI Identification of In Vivo mRNA Decay Intermediates Corresponding to Sites of In Vitro Cleavage by Polyosomal Ribonuclease 1.

AU Hanson M.N.; Schoenberg D.R.  
CS D.R. Schoenberg, Dep. of Molec. and Cell. Biochem., Ohio State University, 1645 Neil Ave., Columbus, OH 43210-1218, United States.  
schoenberg.3@osu.edu  
SO Journal of Biological Chemistry, (13 Apr 2001) Vol. 276, No. 15, pp. 12331-12337..  
Refs: 30  
ISSN: 0021-9258 CODEN: JBCHA3

CY United States  
DT Journal; Article  
FS 029 Clinical Biochemistry  
LA English  
SL English  
ED Entered STN: 4 Dec 2003

Last Updated on STN: 4 Dec 2003

AB Previous work from this laboratory identified a polyosome-associated endonuclease whose activation by estrogen correlates with the coordinate

destabilization of serum protein mRNAs. This enzyme, named polyosomal ribonuclease 1, or PMR-1, is a novel member of the peroxidase gene family. A characteristic feature of PMR-1 is its ability to generate in vitro degradation intermediates by cleaving within overlapping APyRUGA elements in the 5'-coding region of albumin mRNA. The current study sought to determine whether the in vivo destabilization of albumin mRNA following estrogen administration involves the generation of decay intermediates that could be identified as products of PMR-1 cleavage. A sensitive ligation-mediated polymerase chain reaction technique was developed to identify labile decay intermediates, and its validity in identifying PMR-1-generated decay intermediates of albumin mRNA was confirmed by primer extension experiments performed with liver RNA that was isolated from estrogen-treated frogs or digested in vitro with the purified endonuclease. Ligation-mediated polymerase chain reaction was also used to identify decay intermediates from the 3'-end of albumin mRNA, and as a final proof of principle it was employed to identify in vivo decay intermediates of the c-myc \*\*\*coding\*\*\* \*\*\*region\*\*\* \*\*\*instability\*\*\* \*\*\*determinant\*\*\* corresponding to sites of in vitro cleavage by a polyosome-associated endonuclease.

L2 ANSWER 6 OF 9 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 5  
AN 2001372361 EMBASE <>LOGINID::20061120>>  
TI Overexpression of an mRNA-binding protein in human colorectal cancer.  
AU Ross J.; Lemm I.; Berberet B.  
CS J. Ross, University of Wisconsin, McArdle Lab. for Cancer Research, 1400 University Avenue, Madison, WI 53706, United States.  
ross@oncology.wisc.edu

SO Oncogene, (4 Oct 2001) Vol. 20, No. 45, pp. 6544-6550..  
Refs: 26  
ISSN: 0950-9232 CODEN: ONCNES

CY United Kingdom  
DT Journal; Article  
FS 016 Cancer  
022 Human Genetics  
029 Clinical Biochemistry  
LA English  
SL English

ED Entered STN: 2 Nov 2001

Last Updated on STN: 2 Nov 2001

AB A \*\*\*Coding\*\*\* \*\*\*Region\*\*\* \*\*\*instability\*\*\* \*\*\*Determinant\*\*\* -Binding Protein (CRD-BP) binds in vitro to c-myc mRNA and appears to stabilize the mRNA. The CRD-BP gene is amplified in one-third of human breast cancer cases, and the CRD-BP appears to be an oncogenic protein. To analyse CRD-BP expression in human cancer tissue, paired extracts of cancer and normal colon specimens from 21 patients were analysed by immunoblotting and/or reverse transcriptase-polymerase chain reaction. Seventeen cancer specimens out of 21 (81%) were positive for CRD-BP expression by one or both assays. With one exception, normal colon specimens were negative for CRD-BP expression; specimens of inflammatory bowel and a villous adenoma also had no detectable CRD-BP. The lack of CRD-BP expression in normal colon did not result from indiscriminate protein or RNA degradation. c-myc mRNA levels appeared to be elevated in tumor specimens. We conclude that the CRD-BP is scarce or absent from normal colon but is overexpressed in colorectal cancer. The CRD-BP might be a novel human tumor marker.

L2 ANSWER 7 OF 9 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN DUPLICATE 6  
AN 1998383770 EMBASE <>LOGINID::20061120>>

TI The c-myc coding region determinant-binding protein: A member of a family of KH domain RNA-binding proteins.

AU Doyle G.A.R.; Beltz N.A.; Leeds P.F.; Fleisig A.J.; Prokipcak R.D.; Ross J.  
CS J. Ross, McArdle Lab. for Cancer Research, University of Wisconsin-Madison, 1400 University Avenue, Madison, WI 53706, United States.  
ross@oncology.wisc.edu

SO Nucleic Acids Research, (15 Nov 1998) Vol. 26, No. 22, pp. 5036-5044..  
Refs: 60  
ISSN: 0305-1048 CODEN: NARHAD

CY United Kingdom  
DT Journal; Article  
FS 016 Cancer  
022 Human Genetics  
029 Clinical Biochemistry  
LA English  
SL English

ED Entered STN: 3 Dec 1998

Last Updated on STN: 3 Dec 1998

AB The half-life of c-myc mRNA is regulated when cells change their growth rates or differentiate. Two regions within c-myc mRNA determine its short half-life. One is in the 3'-untranslated region, the other is in the coding region. A cytoplasmic protein, the coding region determinant-binding protein (CRD-BP), binds in vitro to the c-myc \*\*\*coding\*\*\* \*\*\*region\*\*\* \*\*\*instability\*\*\* \*\*\*determinant\*\*\*.

We have proposed that the CRD-BP, when bound to the mRNA, shields the mRNA from endonuclease attack and thereby prolongs the mRNA half-life. Here we report the cloning and further characterization of the mouse CRD-BP, a 577 amino acid protein containing four hnRNP K-homology domains,

two RNP domains, an RGG RNA-binding domain and nuclear import and export signals. The CRD-BP is closely related to the chicken beta-actin zipcode-binding protein and is similar to three other proteins, one of which is overexpressed in some human cancers. Recombinant mouse CRD-BP

binds specifically to c-myc CRD RNA in vitro and reacts with antibody against human CRD-BP. Most of the CRD-BP in the cell is cytoplasmic and co-sediments with ribosomal subunits.

L2 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS ON STN  
AN 1992:36307 CAPLUS <>LOGINID::20051120>>  
DN 116:36307  
TI Deadenylylation: a mechanism controlling c-fos mRNA decay  
AU Greenberg, Michael E.; Shyu, Ann Bin; Belasco, Joel G.  
CZ Dep. Microbiol. Mol. Genet., Harvard Med. Sch., Boston, MA, 02115, USA  
SO Enzyme (1991), 44(14), 181-92  
CODEN: ENZYBT; ISSN: 0013-9432  
DT Journal; General Review  
LA English .  
AB A review and discussion with 25 refs. The c-fos proto-oncogene mRNA is extremely labile and is rapidly degraded within minutes after being transported to the cytoplasm of growth factor-stimulated fibroblasts. Anal. of the structural determinants controlling c-fos message decay reveals that this message contains at least 2 functionally independent elements that are responsible for its short half-life. One of these determinants is an AU-rich sequence present in the 3' untranslated region of the c-fos message, whereas the other determinant, which is structurally unrelated to the AU-rich element, is located within the c-fos protein-coding sequence. Both the c-fos AU-rich element and the \*\*\*coding\*\*\* \*\*\*region\*\*\* \*\*\*instability\*\*\* \*\*\*determinant\*\*\* appear to function by facilitating rapid removal of the c-fos poly(A) tail as a first step in the mRNA degradn. process.

L2 ANSWER 9 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on STN  
AN 1992:48190 BIOSIS <<LOGINID:20061120>>  
DN PREV199293028165; BA93.28165  
TI DEADENYLATION A MECHANISM CONTROLLING C-FOS mRNA DECAY.  
AU GREENBERG M E [Reprint author]; SHYU A-B; BELASCO J G  
CS DEP MICROBIOLOGY MOLECULAR GENETICS, HARVARD MED SCH,  
BOSTON, MASS 02115,  
USA  
SO Enzyme (Basel), (1990) Vol. 44, No. 1-4, pp. 181-192.  
CODEN: ENZYBT, ISSN: 0013-9432.  
DT Article  
FS BA  
LA ENGLISH  
ED Entered STN: 13 Jan 1992  
Last Updated on STN: 13 Jan 1992  
AB The c-fos proto-oncogene mRNA is extremely labile and is rapidly degraded within minutes after being transported to the cytoplasm of growth factor-stimulated fibroblasts. Analysis of the structural determinant controlling c-fos message decay reveals that this message contains at least two functionally independent elements that are responsible for its short half-life. One of these determinants is an AU-rich sequence present in the 3' untranslated region of the c-fos message, whereas the other determinant, which is structurally unrelated to the AU-rich element, is located within the c-fos protein-coding sequence. Both the c-fos AU-rich element and the \*\*\*coding\*\*\* \*\*\*region\*\*\* \*\*\*instability\*\*\*  
\*\*\*determinant\*\*\* appear to function by facilitating rapid removal of the c-fos poly(A) tail as a first step in the mRNA degradation process.

FULL ESTIMATED COST	3.24	55.50
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	
TOTAL	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.50
STN INTERNATIONAL LOGOFF AT 15:13:54 ON 20 NOV 2006		

STN INTERNATIONAL LOGOFF AT 15:13:54 ON 20 NOV 2006

L2 ANSWER 9 OF 9 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation  
on STN  
AN 1992:48190 BIOSIS <>LOGINID::20061120>>  
DN PREV199293028165; BA93:28165  
TI DEADENYLATION A MECHANISM CONTROLLING C-FOS mRNA DECAY.  
AU GREENBERG M E [Reprint author]; SHYU A-B; BELASCO J G  
CS DEP MICROBIOLOGY MOLECULAR GENETICS, HARVARD MED SCH,  
BOSTON, MASS 02115,  
USA  
SO Enzyme (Basel), (1990) Vol. 44, No. 1-4, pp. 181-192.  
CODEN: ENZYBT. ISSN: 0013-9432.

DT Article  
FS BA  
LA ENGLISH  
ED Entered STN: 13 Jan 1992  
Last Updated on STN: 13 Jan 1992  
AB The c-fos proto-oncogene mRNA is extremely labile and is rapidly degraded within minutes after being transported to the cytoplasm of growth factor-stimulated fibroblasts. Analysis of the structural determinant controlling c-fos message decay reveals that this message contains at least two functionally independent elements that are responsible for its short half-life. One of these determinants is an AU-rich sequence present in the 3' untranslated region of the c-fos message, whereas the other determinant, which is structurally unrelated to the AU-rich element, is located within the c-fos protein-coding sequence. Both the c-fos AU-rich element and the \*\*\*coding\*\*\* \*\*\*region\*\*\* \*\*\*instability\*\*\* \*\*\*determinant\*\*\* appear to function by facilitating rapid removal of the c-fos poly(A) tail as a first step in the mRNA degradation process.

FILE 'STNGUIDE' ENTERED AT 14:41:45 ON 20 NOV 2006  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM  
KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Nov 17, 2006 (20061117/UP).

$\Rightarrow$

**---Logging off of STN---**

=>

## Executing the logoff script...

=> LOG Y

⇒

**COST IN U.S. DOLLARS**